New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2014
08:08 EDTMMM, NVSEMA committee recommends approval for 3M rivastigmine patch
The EMA's Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Rivastigmine transdermal patches intended for symptomatic treatment of mild to moderately severe Alzheimer's dementia. The applicant for this medicinal product is 3M Health Care (MMM). Rivastigmine 3M Health Care Ltd is a generic of Novartis' (NVS) Exelon.
News For MMM;NVS From The Last 14 Days
Check below for free stories on MMM;NVS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2014
08:40 EDTNVSPositive data on Novartis LCZ696 could raise sales outlook, says Leerink
Subscribe for More Information
August 26, 2014
09:22 EDTMMM3M reaches group purchasing agreement with Premier, Inc
3M Critical & Chronic Care Solutions announces that it has reached a group purchasing agreement with health care alliance company Premier, Inc. for multiple catheter securement and stability products. In a move aimed at bringing greater economic efficiencies to Premier’s more than 100,000 health care provider members, the new agreement allows them to take advantage of special pricing and terms pre-negotiated by Premier. The purchasing contract covers products including Tegaderm CHG Chlorhexidine Gluconate I.V. Securement Dressings and Tegaderm I.V. Advanced Securement Dressings as well as the 3M PICC/ CVC Securement Device + Tegaderm I.V. Advanced Securement Dressing, a sutureless securement system.
August 25, 2014
09:01 EDTMMM3M Company announces investment in Smart Energy Instruments
3M New Ventures – the corporate venture arm of 3M – announced an equity stake in Toronto-based Smart Energy Instruments, a move that will further accelerate SEI’s efforts in developing electronic chipsets with high-precision, real-time monitoring capabilities for smart grids, as well as give 3M a bigger presence in the energy sector. The investment from 3M New Ventures comes as several existing stakeholders also bolstered their equity in SEI, including Venturelink Funds, ArcTern Ventures and the Ontario Capital Growth Corp. Together, the financing round, led by 3M New Ventures, totaled $5M. Other details of the transaction were not disclosed.
August 20, 2014
12:06 EDTNVSNovartis treatment for pigmented villonodular synovitis gets orphan designation
According to a post on the FDA's website, Novartis' recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor received orphan designation. Reference Link
05:17 EDTNVSNovartis provides drug candidate compounds to TB Alliance
Subscribe for More Information
August 19, 2014
05:11 EDTNVSGamida Cell announces investment, option agreement with Novartis
Subscribe for More Information
August 18, 2014
07:35 EDTNVSApricus Biosciences launches topical ED treatment in Germany
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use